Stay updated on Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T17:11:17.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    No Change Detected
  4. Check
    21 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the expected study record, indicating an access restriction or server issue that prevents loading the study details at this time.
    Difference
    19%
    Check dated 2026-09-19T20:16:48.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.5 to v3.6.6, indicating a minor update to the page's version metadata. The study details remain unchanged.
    Difference
    0.1%
    Check dated 2026-08-29T19:09:06.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The revision label on the page was updated from v3.6.4 to v3.6.5. This reflects an internal release update and does not modify the page's substantive content.
    Difference
    0.1%
    Check dated 2026-08-08T18:41:26.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.3 to v3.6.4, indicating a minor platform update; no study details or other content appear to have changed.
    Difference
    0.1%
    Check dated 2026-07-25T12:26:04.000Z thumbnail image
  8. Check
    92 days ago
    Change Detected
    Summary
    The Study Details page now lists Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University as a collaborator and adds a new adverse events outcome (Number of Participants With Adverse Events), along with a defined progression criterion using RECIST v1.0 and a Kaplan-Meier-based follow-up of up to 2 years. The older measure 'Incidence of Adverse Events' and the one-year progression assessment window have been removed.
    Difference
    0.4%
    Check dated 2026-07-11T05:41:52.000Z thumbnail image

Stay in the know with updates to Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab and Nivolumab for Liver Metastatic Uveal Melanoma Clinical Trial page.